Page last updated: 2024-12-10

neurosporene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5280789
CHEBI ID16833
MeSH IDM0052588

Synonyms (18)

Synonym
7,8-dihydro-psi,psi-carotene
neurosporene ,
CHEBI:16833
(6e,8e,10e,12e,14e,16e,18e,20e,22e,26e)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,26,30-dodecaene
LMPR01070086
502-64-7
C05431
all-trans-neurosporene
all-trans neurosporene
psi,psi-carotene, 7,8-dihydro-
unii-fvn22yw634
fvn22yw634 ,
neurosporin
ATCICVFRSJQYDV-XILUKMICSA-N
Q15269719
2,6,8,10,12,14,16,18,20,22,26,30-dotriacontadodecaene, 2,6,10,14,19,23,27,31-octamethyl-
lycopene, 7,8-dihydro-, all-trans-
DTXSID901045315

Research Excerpts

Overview

Neurosporene is a carotene and an intermediate in the synthesis of lycopene from phytoene.

ExcerptReferenceRelevance
"Neurosporene is a carotene and an intermediate in the synthesis of lycopene from phytoene. "( Identification and spectroscopic characterization of neurosporene.
Maoka, T; Takaichi, S, 2015
)
2.11

Bioavailability

ExcerptReferenceRelevance
" Our objective was to compare the bioavailability of lycopene from tangerine to red tomato juice, and elucidate physical deposition forms of these isomers in tomatoes by light and electron microscopy."( Enhanced bioavailability of lycopene when consumed as cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial.
Clinton, SK; Cooperstone, JL; Francis, DM; Haufe, TC; King, SA; Lesinski, GB; Ralston, RA; Riedl, KM; Schwartz, SJ; Schweiggert, RM; Timmers, CD, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acyclic carotene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
u03B2-carotene biosynthesis (engineered)310
trans-lycopene biosynthesis I08
neurosporene biosynthesis07
okenone biosynthesis511
u03B2-carotene biosynthesis (engineered)111
spirilloxanthin and 2,2'-diketo-spirilloxanthin biosynthesis515
spheroidene and spheroidenone biosynthesis612
trans-lycopene biosynthesis I38
trans-lycopene biosynthesis I (bacteria)08
Carotenoid biosynthesis525

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (17.07)18.7374
1990's5 (12.20)18.2507
2000's12 (29.27)29.6817
2010's16 (39.02)24.3611
2020's1 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.80 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.44%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (97.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]